新一代测序与免疫组织化学在MSI/MMR检测中的比较分析。

IF 2.1 Q4 PATHOLOGY
Cisel Aydin Mericoz, Zeynep Secil Satilmis, Fatma Esrefi, Gulsum Caylak, Burcu Saka, Ayse Armutlu, Orhun Cig Taskin, Ibrahim Kulac
{"title":"新一代测序与免疫组织化学在MSI/MMR检测中的比较分析。","authors":"Cisel Aydin Mericoz, Zeynep Secil Satilmis, Fatma Esrefi, Gulsum Caylak, Burcu Saka, Ayse Armutlu, Orhun Cig Taskin, Ibrahim Kulac","doi":"10.5146/tjpath.2025.14079","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Loss of mismatch repair (MMR) protein expression, assessed via immunohistochemistry (IHC), and microsatellite instability (MSI) status, determined through molecular methods, are two tumor-agnostic predictive biomarkers for immunotherapy eligibility. However, there remains no consensus on the preferred testing method, nor on the type and extent of molecular testing required for optimal patient selection. This study investigates the correlation between MMR protein loss detected by IHC and MSI status identified through next-generation sequencing (NGS) to evaluate the concordance and potential complementary roles of these methods.</p><p><strong>Material and methods: </strong>A total of 139 tumor samples were analyzed for MSI using NGS. The cohort included colorectal carcinoma (n=51), pancreatic ductal adenocarcinoma (n=22), cholangiocarcinoma (n=9), non-small cell lung carcinoma (n=6), adenoid cystic carcinoma (n=6), gastric adenocarcinoma (n=6), high-grade serous ovarian carcinoma (n=5), and 34 other tumor types. IHC was performed to assess MLH1, MSH2, MSH6, and PMS2 protein expression. The correlation between MSI status and MMR protein loss was evaluated.</p><p><strong>Results: </strong>Twelve tumors (8.6%) were classified as MSI-High (microsatellite instable). Among them, ten exhibited MMR protein loss, whereas two MSI-High tumors (a mucinous adenocarcinoma of omental origin and a mucinous colon adenocarcinoma) retained MMR protein expression. No MMR-deficient tumors were identified as MSI-Low (microsatellite stable/MSS).</p><p><strong>Conclusion: </strong>A strong correlation exists between IHC-based MMR loss and NGS-based MSI detection. IHC remains widely used due to its accessibility and cost-effectiveness, whereas NGS offers higher accuracy and broader genomic insights. With its ability to detect multiple alterations simultaneously, NGS is particularly valuable when tissue is scarce. Combining both methods can improve diagnostic accuracy and guide optimal immunotherapy selection.</p>","PeriodicalId":45415,"journal":{"name":"Turkish Journal of Pathology","volume":" ","pages":"105-112"},"PeriodicalIF":2.1000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comparative Analysis of Next-Generation Sequencing and Immunohistochemistry in MSI/MMR Testing.\",\"authors\":\"Cisel Aydin Mericoz, Zeynep Secil Satilmis, Fatma Esrefi, Gulsum Caylak, Burcu Saka, Ayse Armutlu, Orhun Cig Taskin, Ibrahim Kulac\",\"doi\":\"10.5146/tjpath.2025.14079\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Loss of mismatch repair (MMR) protein expression, assessed via immunohistochemistry (IHC), and microsatellite instability (MSI) status, determined through molecular methods, are two tumor-agnostic predictive biomarkers for immunotherapy eligibility. However, there remains no consensus on the preferred testing method, nor on the type and extent of molecular testing required for optimal patient selection. This study investigates the correlation between MMR protein loss detected by IHC and MSI status identified through next-generation sequencing (NGS) to evaluate the concordance and potential complementary roles of these methods.</p><p><strong>Material and methods: </strong>A total of 139 tumor samples were analyzed for MSI using NGS. The cohort included colorectal carcinoma (n=51), pancreatic ductal adenocarcinoma (n=22), cholangiocarcinoma (n=9), non-small cell lung carcinoma (n=6), adenoid cystic carcinoma (n=6), gastric adenocarcinoma (n=6), high-grade serous ovarian carcinoma (n=5), and 34 other tumor types. IHC was performed to assess MLH1, MSH2, MSH6, and PMS2 protein expression. The correlation between MSI status and MMR protein loss was evaluated.</p><p><strong>Results: </strong>Twelve tumors (8.6%) were classified as MSI-High (microsatellite instable). Among them, ten exhibited MMR protein loss, whereas two MSI-High tumors (a mucinous adenocarcinoma of omental origin and a mucinous colon adenocarcinoma) retained MMR protein expression. No MMR-deficient tumors were identified as MSI-Low (microsatellite stable/MSS).</p><p><strong>Conclusion: </strong>A strong correlation exists between IHC-based MMR loss and NGS-based MSI detection. IHC remains widely used due to its accessibility and cost-effectiveness, whereas NGS offers higher accuracy and broader genomic insights. With its ability to detect multiple alterations simultaneously, NGS is particularly valuable when tissue is scarce. Combining both methods can improve diagnostic accuracy and guide optimal immunotherapy selection.</p>\",\"PeriodicalId\":45415,\"journal\":{\"name\":\"Turkish Journal of Pathology\",\"volume\":\" \",\"pages\":\"105-112\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Turkish Journal of Pathology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5146/tjpath.2025.14079\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PATHOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5146/tjpath.2025.14079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:失配修复(MMR)蛋白表达缺失,通过免疫组织化学(IHC)评估,微卫星不稳定性(MSI)状态,通过分子方法确定,是免疫治疗资格的两种肿瘤不可知的预测性生物标志物。然而,对于首选的检测方法,以及最佳患者选择所需的分子检测的类型和范围,仍然没有达成共识。本研究探讨了IHC检测的MMR蛋白丢失与下一代测序(NGS)鉴定的MSI状态之间的相关性,以评估这两种方法的一致性和潜在的互补作用。材料与方法:采用NGS对139例肿瘤标本进行MSI分析。该队列包括结直肠癌(51例)、胰管腺癌(22例)、胆管癌(9例)、非小细胞肺癌(6例)、腺样囊性癌(6例)、胃腺癌(6例)、高级别浆液性卵巢癌(5例)和其他34种肿瘤类型。免疫组化检测MLH1、MSH2、MSH6和PMS2蛋白表达。评估MSI状态与MMR蛋白损失之间的相关性。结果:12例(8.6%)肿瘤为msi -高(微卫星不稳定)。其中10例表现出MMR蛋白缺失,而2例msi -高肿瘤(网膜源性粘液腺癌和黏液性结肠腺癌)保留了MMR蛋白表达。没有mmr缺陷肿瘤被鉴定为MSI-Low(微卫星稳定/MSS)。结论:基于ihc的MMR损失与基于ngs的MSI检测之间存在很强的相关性。由于其可及性和成本效益,IHC仍然被广泛使用,而NGS提供更高的准确性和更广泛的基因组见解。NGS具有同时检测多种变化的能力,在组织稀缺时尤其有价值。两种方法相结合可提高诊断准确性,指导最佳免疫治疗方案的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparative Analysis of Next-Generation Sequencing and Immunohistochemistry in MSI/MMR Testing.

Objective: Loss of mismatch repair (MMR) protein expression, assessed via immunohistochemistry (IHC), and microsatellite instability (MSI) status, determined through molecular methods, are two tumor-agnostic predictive biomarkers for immunotherapy eligibility. However, there remains no consensus on the preferred testing method, nor on the type and extent of molecular testing required for optimal patient selection. This study investigates the correlation between MMR protein loss detected by IHC and MSI status identified through next-generation sequencing (NGS) to evaluate the concordance and potential complementary roles of these methods.

Material and methods: A total of 139 tumor samples were analyzed for MSI using NGS. The cohort included colorectal carcinoma (n=51), pancreatic ductal adenocarcinoma (n=22), cholangiocarcinoma (n=9), non-small cell lung carcinoma (n=6), adenoid cystic carcinoma (n=6), gastric adenocarcinoma (n=6), high-grade serous ovarian carcinoma (n=5), and 34 other tumor types. IHC was performed to assess MLH1, MSH2, MSH6, and PMS2 protein expression. The correlation between MSI status and MMR protein loss was evaluated.

Results: Twelve tumors (8.6%) were classified as MSI-High (microsatellite instable). Among them, ten exhibited MMR protein loss, whereas two MSI-High tumors (a mucinous adenocarcinoma of omental origin and a mucinous colon adenocarcinoma) retained MMR protein expression. No MMR-deficient tumors were identified as MSI-Low (microsatellite stable/MSS).

Conclusion: A strong correlation exists between IHC-based MMR loss and NGS-based MSI detection. IHC remains widely used due to its accessibility and cost-effectiveness, whereas NGS offers higher accuracy and broader genomic insights. With its ability to detect multiple alterations simultaneously, NGS is particularly valuable when tissue is scarce. Combining both methods can improve diagnostic accuracy and guide optimal immunotherapy selection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.90
自引率
10.00%
发文量
23
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信